Edition:
United States

Zhejiang Hisun Pharmaceutical Co Ltd (600267.SS)

600267.SS on Shanghai Stock Exchange

14.03CNY
12:28am EST
Change (% chg)

¥-0.17 (-1.20%)
Prev Close
¥14.20
Open
¥14.15
Day's High
¥14.38
Day's Low
¥14.02
Volume
4,906,116
Avg. Vol
7,711,050
52-wk High
¥16.70
52-wk Low
¥10.24

Chart for

About

Zhejiang Hisun Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the research and development, manufacture and distribution of specialty bulk pharmaceutical chemicals and preparation products. The Company's bulk pharmaceutical chemicals mainly include antineoplastic drugs, cardiovascular drugs, anti-infec... (more)
No analyst recommendations are available for .

Overall

Beta: 1.21
Market Cap(Mil.): ¥13,053.99
Shares Outstanding(Mil.): 965.53
Dividend: 0.05
Yield (%): 0.37

Financials

  Industry Sector
P/E (TTM): -- 32.13 15.67
EPS (TTM): -- -- --
ROI: -- 15.10 34.62
ROE: -- 16.59 16.00

BRIEF-Zhejiang Hisun Pharmaceutical's share trade to resume after Pfizer exited China JV

* SAYS SHARE TRADE TO RESUME ON NOV 29 AFTER PFIZER EXITED CHINA JOINT VENTURE WITH THE COMPANY Source text in Chinese: http://bit.ly/2iZ534b Further company coverage: (Reporting by Hong Kong newsroom)

Nov 28 2017

BRIEF-Zhejiang Hisun Pharmaceutical passes FDA approval

* Says it received approval for a kind of tablet from U.S Food and Drug Administration

Nov 21 2017

BRIEF-Zhejiang Hisun Pharmaceutical to issue up to 3.0 bln yuan commercial paper

* Says it plans to issue up to 3.0 billion yuan ($452.59 million) ultra-short commercial paper

Nov 20 2017

BRIEF-Zhejiang Hisun Pharmaceutical unit says product gets FDA approval

* Says co's Hangzhou-based unit's product simvastatin tablets, gets approval from U.S. Food and Drug Administration

Nov 20 2017

Pfizer exits China joint venture for generic drugs

Pfizer Inc said on Friday it has sold its 49 percent stake to exit a joint venture it had set up with China's Zhejiang Hisun Pharmaceuticals in 2012 to develop and market generic drugs.

Nov 10 2017

Pfizer exits China joint venture for generic drugs

Nov 10 Pfizer Inc said on Friday it has sold its 49 percent stake to exit a joint venture it had set up with China's Zhejiang Hisun Pharmaceuticals in 2012 to develop and market generic drugs.

Nov 10 2017

BRIEF-Zhejiang Hisun Pharmaceutical receives TGA-GMP certificate

* Says it received goods manufacture practice (GMP) certificate from Therapeutic Goods Administration

Oct 11 2017

BRIEF-Zhejiang Hisun Pharmaceutical to invest 5.1 mln yuan to set up investment management JV

* Says it will invest 5.1 million yuan to set up Zhejiang-based investment management JV, which will be engaged in operation of pharmaceutical industry innovation projects, and hold 51 percent stake in JV after transaction

Sep 26 2017

BRIEF-Zhejiang Hisun Pharmaceutical plans to sell stake in Germany's INS

* Says it plans to sell its entire 21.05 percent stake in Germany's IMD Natural Solutions GmbH (INS)

Sep 26 2017

BRIEF-Zhejiang Hisun Pharmaceutical sub-subsidiary passes FDA approval

* Says its Zhejiang-based sub-subsidiary received FDA approval for metformin sustained release tablet from U.S Food and Drug Administration

Sep 11 2017

Earnings vs. Estimates